A federal plan could open pharmacy access to popular peptides

On October 15, 2026, a government website showed that the Department of Health and Human Services had sent a peptide “interim access policy” to the White House for review. The policy text has not been published. Reporting describes it as a way to let licensed compounding pharmacies make some popular peptides, BPC-157 among them, for a limited time while the FDA works out permanent rules.

What it reportedly does

The mechanism described is enforcement discretion: the FDA would signal that it will not take action against pharmacies that compound certain peptides during the interim period. Nothing in the law changes. The agency would simply choose not to enforce some of its own rules for these products.

The permanent route is different. Adding a peptide to the list of ingredients pharmacies may compound requires federal rulemaking with public comment, which can take a year or more. It is not yet clear whether the administration will pursue that route as well.

What it would not do

• Approve anything. The peptides would remain unapproved drugs.
• Establish that they work or are safe. FDA staff scientists concluded earlier this year that none of the peptides reviewed had been studied enough to establish either.
• Override state law on prescribing and on how compounded medicines are dispensed.

What is still unknown

Which peptides are covered, under what conditions, and from what date. HHS did not respond to STAT’s request for comment. A Bloomberg headline on October 22 described the plan as requiring compounding pharmacies to report side effects; until the text is public, the details of that requirement are not confirmed.

How it got here

This is the latest step in a year of changes to how the FDA treats compounded peptides, including an April decision to take twelve peptides off its “significant safety concerns” list and a July advisory-committee vote. The full timeline is in Are peptides legal in the US?